Literature DB >> 7140568

[Antithrombin III substitution in dialysis-dependent renal insufficiency].

J Schrader, H Köstering, P Kramer, F Scheler.   

Abstract

Haemodialysis had become impossible or possible only using high doses of heparin in 20 patients with dialysis-dependent renal insufficiency due to lowering of antithrombin III (AT III). In order to assess the value of AT III substitution for effective heparin treatment and concomitant diminution of the danger of haemorrhage AT III substitution was done in these patients. Six patients. Six patients with acute renal failure and disseminated intravascular coagulation were able to undergo dialysis using only 750-1000 IU heparin/h after normalisation of AT III without complications. In 3 patients thrombosing of the extracorporeal system had occurred despite increasing doses of heparin; only after 1500 U AT III subsequent haemodialysis could be performed without thromboses. Dialysis was performed with continuous substitution of the AT III-heparin-complex in 6 patients prone to haemorrhage. 250-500 U of AT III-heparin-complex were sufficient and proved as safe and well manageable possibility of minimal anticoagulation. In 5 patients repeated thrombosing of the haemofilter per day had occurred during continuous arteriovenous haemofiltration. After AT III administration haemofilters could be left in situ for 18-46 hours.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7140568     DOI: 10.1055/s-2008-1070219

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  [Use of low molecular-weight heparin in hemodialysis patients].

Authors:  J Schrader; J Rieger; H Müschen; W Stibbe; H Köstering; P Kramer; F Scheler
Journal:  Klin Wochenschr       Date:  1985-01-15

Review 2.  SerpinC1/Antithrombin III in kidney-related diseases.

Authors:  Zeyuan Lu; Feng Wang; Mingyu Liang
Journal:  Clin Sci (Lond)       Date:  2017-05-01       Impact factor: 6.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.